Scilex Relaunch Elyxyb (celecoxib oral solution) in the US for Migraine Treatment
- The company reported the commercial availability of Elyxyb (celecoxib oral solution), the ready-to-use oral solution formulation of celecoxib for the acute treatment of migraine with/out aura in the US.
- Elyxyb is expected to be available in the US in Q2’23 through its wholly owned subsidiary, Scilex & has been approved in the US on May 2020 for the treatment of acute migraine with or without aura in adults, based on the 2 P-III trials.
- Elyxyb is now available in pharmacies as an oral solution in glass bottles with a celecoxib concentration of 25mg per mL (120mg/4.8 mL) & the maximum dosage in a 24hr. period is 120mg. The company also strengthen its leadership position in non-opioid pain management
Ref: Globenewswire | Image: Scilex
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.